Introduction
============

Diabetes mellitus (DM) has reached epidemic proportions and affects more than 382 million individuals worldwide ([@b1-br-0-0-1105]): The number of patients with DM is expected to increase beyond 592 million individuals by 2035 ([@b1-br-0-0-1105]). Approximately 90 to 95% of individuals with DM have type 2 DM (T2DM), the characteristics of which can range from predominant insulin deficiency with relatively minor insulin resistance to predominant insulin resistance with relatively minor insulin deficiency ([@b2-br-0-0-1105]). T2DM is a major cause of nephropathy, retinopathy, and neuropathy as well as cardiovascular disease and stroke ([@b3-br-0-0-1105],[@b4-br-0-0-1105]). Although obesity resulting from a sedentary lifestyle and overeating is an important risk factor for T2DM, genetic components are involved in the pathogenesis of this condition, given that a positive family history confers a 2.4-fold increased risk for T2DM ([@b5-br-0-0-1105]). The heritability of T2DM has been estimated to be 50 to 60% ([@b6-br-0-0-1105]).

Genome-wide association studies (GWASs) and meta-analyses have identified \>120 susceptibility loci for T2DM ([@b7-br-0-0-1105]) in individuals of European ([@b8-br-0-0-1105]--[@b13-br-0-0-1105]) or African ([@b14-br-0-0-1105]) ancestry, in East Asians ([@b15-br-0-0-1105]), or in multiple ethnic groups ([@b16-br-0-0-1105],[@b17-br-0-0-1105]). Among Japanese, GWASs have identified *KCNQ1, UBE2E2*, and *C2CD4A-B* ([@b18-br-0-0-1105]--[@b20-br-0-0-1105]) as susceptibility genes for T2DM, and a recent meta-analysis identified an additional seven susceptibility loci for this condition ([@b21-br-0-0-1105]). Genetic variants that contribute to predisposition to T2DM in Japanese subjects, however, remain to be identified definitively.

Metabolic syndrome (MetS) is a cluster of metabolic traits including abdominal obesity, an increased serum triglycerides, a decreased serum high-density lipoprotein (HDL) cholesterol, high blood pressure (BP), and an increased fasting plasma glucose (FPG) level ([@b22-br-0-0-1105]). MetS is a risk factor for atherosclerotic cardiovascular disease, DM ([@b23-br-0-0-1105]), and cancer ([@b24-br-0-0-1105]). The etiology of MetS is highly complex, with both genetic and environmental factors being thought to play important roles. The heritability of MetS has been estimated to be approximately 50% ([@b25-br-0-0-1105]) and traits of this syndrome to be 28 to 48% ([@b26-br-0-0-1105]).

GWASs have suggested various loci or genes involved in predisposition to MetS or to traits of this syndrome in individuals of European ([@b27-br-0-0-1105],[@b28-br-0-0-1105]) or African ([@b29-br-0-0-1105]) ancestry or in Asian Indians ([@b30-br-0-0-1105]) or Chinese individuals ([@b31-br-0-0-1105]). However, genetic variants that contribute to predisposition to MetS in Japanese individuals remain to be identified definitively.

Circulating uric acid levels are regulated by multiple renal transporters by mediating the excretion or reabsorption of uric acid in the proximal kidney tubules ([@b32-br-0-0-1105]). Hyperuricemia is an important risk factor for gout, a common inflammatory arthritis ([@b33-br-0-0-1105]), as well as for cardiovascular disease ([@b34-br-0-0-1105]) and cancer ([@b35-br-0-0-1105]). The heritability of the serum concentration of uric acid has been estimated to be 40% ([@b36-br-0-0-1105]), suggesting that genetic variants contribute to regulation of the serum uric acid level by influencing uric acid synthesis, excretion, or reabsorption ([@b36-br-0-0-1105],[@b37-br-0-0-1105]).

GWASs have identified single nucleotide polymorphisms (SNPs) significantly associated with the serum uric acid concentration or the prevalence of gout ([@b38-br-0-0-1105]--[@b45-br-0-0-1105]). A large-scale GWAS in European ancestry populations identified 28 loci that influence the serum concentration of uric acid ([@b46-br-0-0-1105]). Although several SNPs have been shown to be associated with gout in Japanese ([@b47-br-0-0-1105],[@b48-br-0-0-1105]), genetic variants that contribute to predisposition to hyperuricemia in Japanese remain to be identified definitively.

In a family study of T2DM, a heritability of T2DM was higher in early-onset than late-onset individuals ([@b6-br-0-0-1105]). These observations indicate that early-onset T2DM has a strong genetic component ([@b6-br-0-0-1105],[@b49-br-0-0-1105]). Similar to T2DM, early-onset forms of MetS ([@b50-br-0-0-1105],[@b51-br-0-0-1105]), hyperuricemia, and gout ([@b52-br-0-0-1105],[@b53-br-0-0-1105]) have been shown to have strong genetic components. Given that genetic contribution may be greater in early-onset forms of T2DM, MetS, and hyperuricemia than in late-onset forms, statistical power of the genetic association study may be increased by focusing on early-onset subjects with these conditions.

In the present study, we performed exome-wide association studies (EWASs) with the use of human exome array-based genotyping methods to identify genetic variants that confer susceptibility to early-onset T2DM, MetS, or hyperuricemia in Japanese patients. To increase the statistical power of EWASs, early-onset subjects were examined.

Materials and methods
=====================

### Study subjects

In previous studies, the median age of subjects with T2DM ([@b54-br-0-0-1105]), MetS ([@b55-br-0-0-1105]), or hyperuricemia ([@b56-br-0-0-1105]) was 68, 64, or 62 years, respectively. We thus defined subjects aged ≤65 years as early-onset cases in the present study. A total of 8,102 individuals aged ≤65 years were examined. The subjects were recruited from individuals either who visited outpatient clinics of or were admitted to participating hospitals in Japan (Gifu Prefectural Tajimi Hospital, Tajimi; Gifu Prefectural General Medical Center, Gifu; Japanese Red Cross Nagoya First Hospital, Nagoya; Northern Mie Medical Center Inabe General Hospital, Inabe; Hirosaki University Hospital and Hirosaki Stroke and Rehabilitation Center, Hirosaki) because of various symptoms or for an annual health checkup between October 2002 and March 2014; or who were community-dwelling individuals recruited to a population-based cohort study in Inabe between March 2010 and september 2014 ([@b57-br-0-0-1105]).

T2DM was defined according to the criteria of the World Health Organization as described previously ([@b2-br-0-0-1105],[@b58-br-0-0-1105],[@b59-br-0-0-1105]). Subjects with T2DM had an FPG level of ≥6.93 mmol/l (126 mg/dl) or a blood hemoglobin A~1c~ content of ≥6.5% or were taking antidiabetes medication. Individuals with T1DM, maturity-onset diabetes of the young, DM associated with mitochondrial diseases or single-gene disorders, pancreatic diseases, or other metabolic or endocrinologic diseases were excluded from the study. Those taking medications that may cause secondary DM were also excluded. The control subjects had an FPG level of \<6.05 mmol/l (110 mg/dl), a blood hemoglobin A~1c~ content of \<6.2%, and no history of DM or of having taken antidiabetes medication. We thus examined 1,696 subjects with T2DM and 5,711 controls.

Diagnosis of MetS was based on a modified version of the definition proposed by the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity ([@b22-br-0-0-1105]). We used cut-off values for waist circumference of ≥90 cm in men or ≥80 cm in women on the basis of a recommendation of the International Diabetes Association ([@b22-br-0-0-1105]). A total of 2,296 subjects with MetS thus had three or more of the following five components: i) A waist circumference of ≥90 cm for men or ≥80 cm for women; ii) a serum triglyceride concentration of ≥1.65 mmol/l (150 mg/dl) or drug treatment for elevated triglycerides; iii) a serum HDL-cholesterol concentration of \<1.04 mmol/l (40 mg/dl) for men or \<1.30 mmol/l (50 mg/dl) for women; iv) a systolic BP of ≥130 mmHg, diastolic BP of ≥85 mmHg, or drug treatment for hypertension; and v) an FPG level of ≥5.50 mmol/l (100 mg/dl) or drug treatment for elevated glucose. History of obesity, dyslipidemia, hypertension, or DM was evaluated with a detailed questionnaire. The control subjects comprised 1,919 individuals who had none of the five traits of MetS.

Hyperuricemia was defined as a serum uric acid concentration of \>416 µmol/l (7 mg/dl) or taking of uric acid-lowering medication. Individuals taking drugs that potentially caused secondary hyperuricemia were excluded. The control individuals for the study of hyperuricemia had a serum uric acid concentration of ≤416 µmol/l and had no history of hyperuricemia or gout or of taking uric acid-lowering medication. Thus, we examined 1,365 subjects with hyperuricemia and 6,554 controls.

The 1,040 subjects with both T2DM and MetS as well as 1,884 controls overlapped between the corresponding studies, as did the 375 subjects with both T2DM and hyperuricemia and 4,809 controls as well as the 628 subjects with both MetS and hyperuricemia and 1,771 controls.

### EWASs

Venous blood (5--7 ml) was collected into tubes containing 50 mmol/l ethylenediaminetetraacetic acid (disodium salt), peripheral blood leukocytes were isolated, and genomic DNA was extracted from these cells either with the use of a kit (Genomix from Talent Srl, Trieste, Italy or SMITEST EX-R&D from Medical & Biological Laboratories, Co., Ltd., Nagoya, Japan).

The EWAS for T2DM, MetS, or hyperuricemia included 7,407 individuals (1,696 subjects with T2DM, 5,711 controls), 4,215 individuals (2,296 subjects with MetS, 1,919 controls), or 7,919 individuals (1,365 subjects with hyperuricemia, 6,554 controls), respectively. The EWASs were performed with the use of a Human Exome-12 v1.2 DNA Analysis BeadChip or Infinium Exome-24 v1.0 BeadChip (Illumina, San Diego, CA, USA). These exome arrays include putative functional exonic variants selected from \~12,000 individual exome and whole-genome sequences. The exonic content consisted of \~244,000 SNPs from diverse populations, including European, African, Chinese, and Hispanic individuals ([@b60-br-0-0-1105]). SNPs contained in only one exome array (\~2.6% of all SNPs) were excluded from analysis. We performed quality control ([@b61-br-0-0-1105]) as follows: i) Genotyping data with a call rate of \<97% were discarded, with the mean call rate for the remaining data being 99.9%. ii) Sex specification was checked for all the samples, and those for which sex phenotype in the clinical records was inconsistent with genetic sex were discarded. iii) Duplicated samples and cryptic relatedness were checked by calculation of identity by descent, with all the pairs of samples showing a value of \>0.1875 being inspected and one sample from each pair excluded. iv) Heterozygosity of SNPs was calculated for all the samples, and those with extremely low or high heterozygosity (\>3 standard deviations from the mean) were discarded. v) SNPs in sex chromosomes or mitochondrial DNA were excluded from the analysis, as were non-polymorphic SNPs or SNPs with a minor allele frequency of \<1.0%. vi) SNPs whose genotype distributions deviated significantly (P\<0.01) from the Hardy-Weinberg equilibrium in control individuals were discarded. vii) Genotype data were examined for population stratification by principal components analysis ([@b62-br-0-0-1105]), and population outliers were excluded. Totals of 31,210, 31,521, or 31,142 SNPs passed quality control for the T2DM, MetS, and hyperuricemia studies, respectively, and were subjected to analysis.

### Statistical analysis

For analysis of characteristics of the study subjects, quantitative or categorical data were compared between individuals with T2DM, MetS, or hyperuricemia and corresponding controls with the unpaired Student\'s t-test or Pearson\'s Chi-square test, respectively. Allele frequencies were estimated by the gene counting method, and Fisher\'s exact test was used to identify departure from Hardy-Weinberg equilibrium. The relationship of allele frequencies of SNPs to T2DM, MetS, or hyperuricemia in the EWAS was examined using the Fisher\'s exact test. To compensate for multiple comparisons of allele frequencies with T2DM, MetS, or hyperuricemia, we applied Bonferroni\'s correction for statistical significance of association. The significance level was set at P\<1.60×10^−6^ (0.05/31210), P\<1.59×10^−6^ (0.05/31521), or P\<1.61×10^−6^ (0.05/31142) for the EWAS of T2DM, MetS, or hyperuricemia, respectively. The inflation factor (λ) was 1.04 for T2DM, 1.05 for MetS, or 1.09 for hyperuricemia. Multivariable logistic regression analysis was performed with T2DM, MetS, hyperuricemia as a dependent variable and independent variables including age, sex (0, woman; 1, man), and genotype of each SNP. Genotypes of each SNP were assessed according to dominant \[0, *AA*; 1, *AB* + *BB* (*A*, major allele; *B*, minor allele)\], recessive (0, *AA* + *AB*; 1, *BB*), and additive genetic models, and the P-value, OR, and 95% confidence interval were calculated. Additive models comprised additive 1 (0, *AA*; 1, *AB*; 0, *BB*) and additive 2 (0, *AA*; 0, *AB*; 1, *BB*) scenarios, which were analyzed simultaneously with a single statistical model. The relation of genotypes of identified SNPs to T2DM-, MetS-, or hyperuricemia-related traits was examined by one-way analysis of variance (ANOVA). Bonferroni\'s correction was also applied to other statistical analysis as indicated. Statistical tests were performed with JMP Genomics version 9.0 software (SAS Institute, Cary, NC, USA).

Results
=======

### Characteristics of subjects

The characteristics of the 7,407 subjects enrolled in the T2DM study are shown in [Table I](#tI-br-0-0-1105){ref-type="table"}. Age, the frequency of men, and the prevalence of obesity, hypertension, dyslipidemia, chronic kidney disease (CKD), and hyperuricemia as well as body mass index (BMI), systolic and diastolic BP, and serum concentrations of triglycerides, creatinine, and uric acid were greater, whereas serum concentration of HDL-cholesterol and estimated glomerular filtration rate (eGFR) were lower, in subjects with T2DM than in controls.

Characteristics of the 4,215 subjects enrolled in the MetS study are shown in [Table II](#tII-br-0-0-1105){ref-type="table"}. Age, the frequency of men, and the prevalence of smoking, CKD, and hyperuricemia as well as BMI, blood hemoglobin A~1c~ content, and serum concentrations of low-density lipoprotein (LDL) cholesterol, creatinine, and uric acid were greater, whereas eGFR were lower, in subjects with MetS than in controls.

Characteristics of the 7,919 subjects enrolled in the hyperuricemia study are shown in [Table III](#tIII-br-0-0-1105){ref-type="table"}. Age, the frequency of men, and the prevalence of smoking, obesity, hypertension, DM, dyslipidemia, and CKD as well as BMI, systolic and diastolic BP, FPG level, and serum concentrations of triglycerides and creatinine were greater, whereas the serum concentration of HDL-cholesterol and eGFR were lower, in subjects with hyperuricemia than in controls.

### EWAS for T2DM, MetS, or hyperuricemia

We examined the relationship of allele frequencies of 31,210 SNPs that passed quality control to T2DM with the use of Fisher\'s exact test. After Bonferroni\'s correction, four SNPs were significantly (P\<1.60×10^−6^) associated with T2DM ([Table IV](#tIV-br-0-0-1105){ref-type="table"}). The relationship of allele frequencies of 31,521 SNPs to MetS was examined with Fisher\'s exact test. After Bonferroni\'s correction, six SNPs were significantly (P\<1.59×10^−6^) associated with MetS ([Table V](#tV-br-0-0-1105){ref-type="table"}). The relationship of allele frequencies of 31,142 SNPs to hyperuricemia was also examined with Fisher\'s exact test. After Bonferroni\'s correction, nine SNPs were significantly (P\<1.61×10^−6^) associated with hyperuricemia ([Table VI](#tVI-br-0-0-1105){ref-type="table"}).

### Multivariable logistic regression analysis of the relationship of SNPs to T2DM, MetS, or hyperuricemia

The relationship of the four identified SNPs in the EWAS of T2DM to this condition was further examined by multivariable logistic regression analysis with adjustment for age and sex ([Table VII](#tVII-br-0-0-1105){ref-type="table"}). Three SNPs (rs141569282 of *OR4F6*, rs140232911 of *ZNF860*, rs150552771 of *LPGAT1*) were significantly \[P\<0.0031 (0.05/16) in at least one genetic model\] related to T2DM. The relationship of the six SNPs identified in the EWAS for MetS to this condition was examined by multivariable logistic regression analysis with adjustment for age and sex ([Table VIII](#tVIII-br-0-0-1105){ref-type="table"}). All the SNPs were significantly \[P\<0.0021 (0.05/24)\] related to MetS. The relationship of the 9 SNPs identified by the EWAS of hyperuricemia to this condition was also examined by multivariable logistic regression analysis with adjustment for age and sex ([Table IX](#tIX-br-0-0-1105){ref-type="table"}). All SNPs were significantly \[P\<0.0014 (0.05/36)\] related to hyperuricemia.

### Relationship of SNPs associated with T2DM to FPG level or blood hemoglobin A~1c~ content

We examined the relationship of genotypes for the 3 SNPs associated with T2DM to FPG level or blood hemoglobin A~1c~ content by one-way ANOVA ([Table X](#tX-br-0-0-1105){ref-type="table"}). A SNP rs141569282 of *OR4F6* was significantly \[P\<0.0083 (0.05/6)\] associated with FPG level and blood hemoglobin A~1c~ content, and rs140232911 of *ZNF860* with blood hemoglobin A~1c~ content.

### Relationship of SNPs associated with MetS to each trait of MetS

We examined the relationship of genotypes for the six SNPs associated with MetS to waist circumference, serum concentrations of triglycerides and HDL-cholesterol, systolic and diastolic BP, and FPG level by one-way ANOVA ([Table XI](#tXI-br-0-0-1105){ref-type="table"}). Three SNPs (rs1053266 of *CCDC6*, rs141569282 of *OR4F6*, rs200716952 of *HLA-DQB2*) were significantly (P\<0.0014) related to all the traits; rs2075291 of *APOA5* to waist circumference and serum concentrations of triglycerides and HDL-cholesterol; rs11823828 of *OR52E4* to serum concentrations of triglycerides and HDL-cholesterol, systolic BP, and FPG level; and rs17482753 at chromosome 8p21.3 to serum concentrations of triglycerides and HDL-cholesterol.

### Relationship of SNPs associated with hyperuricemia to serum concentrations of uric acid

We examined the relationship of the 9 SNPs associated with hyperuricemia to serum concentrations of uric acid by one-way ANOVA ([Table XII](#tXII-br-0-0-1105){ref-type="table"}). Seven SNPs (rs121907892 of *SLC22A12*, rs3782886 of *BRAP*, rs11066015 of *ACAD10*, rs11066280 of *HECTD4*, rs12229654 at chromosome 12q24.1, rs3775948 of *SLC2A9*, rs2305335 of *HERPUD2*) were significantly (P\<0.0056) associated with serum concentrations of uric acid.

### Linkage disequilibrium (LD) analyses

We examined LD in SNPs associated with MetS or hyperuricemia. For the MetS study, rs11823828 of *OR52E4* and rs2075291 of *APOA5* were not in LD \[square of the correlation coefficient (r^2^)\<0.001\]. For the hyperuricemia study, 6 SNPs were located at chromosomal 12q24.11 to 12q24.13. LD plots of these SNPs are shown in [Fig. 1](#f1-br-0-0-1105){ref-type="fig"}. Strong LD was observed between rs10849915 and rs10774610 of *CCDC63* (r^2^, 0.991) and among rs3782886 of *BRAP*, rs11066015 of *ACAD10*, and rs11066280 of *HECTD4* (r^2^, 0.876 to 0.941).

Relation of genes, chromosomal loci, and SNPs identified in the present study to phenotypes reported by previous GWASs. We examined the genes, chromosomal loci, and SNPs identified in the present study to phenotypes previously reported by GWASs available in Genome-Wide Repository of Associations Between SNPs and Phenotypes (GRASP) Search database (<https://grasp.nhlbi.nih.gov/Search.aspx>) developed by the Information Technology and Applications Center, National Center for Biotechnology Information, National Heart, Lung, and Blood Institute, National Institute of Health (Bethesda, MD, USA).

In the T2DM study, none of the three genes or SNPs was shown to be associated with T2DM or diabetes-related traits in previous GWASs ([Table XIII](#tXIII-br-0-0-1105){ref-type="table"}). In the MetS study, *HLA-DQB2* was shown to be related to T1DM and plasma total cholesterol; rs17482753 at chromosome 8p21.3 to plasma concentrations of triglycerides and HDL-cholesterol; *CCDC6* to serum uric acid level; and *APOA5* to plasma concentrations of triglycerides, HDL-cholesterol, and LDL-cholesterol ([Table XIV](#tXIV-br-0-0-1105){ref-type="table"}). In the hyperuricemia study, *SLC2A9, SLC22A12*, and *BRAP* were shown to be related to serum uric acid concentrations; rs12229654 at 12q24.1 to plasma HDL-cholesterol; *ACAD10* to plasma LDL-cholesterol and T1DM; and *HECTD4* to plasma HDL-cholesterol and LDL-cholesterol and FPG level ([Table XV](#tXV-br-0-0-1105){ref-type="table"}).

Discussion
==========

T2DM, MetS, and hyperuricemia are important public health problems because of the high prevalence of these conditions as well as risk factors for more serious conditions such as cardiovascular disease, cancer, or gout ([@b1-br-0-0-1105],[@b3-br-0-0-1105],[@b4-br-0-0-1105],[@b23-br-0-0-1105],[@b24-br-0-0-1105],[@b33-br-0-0-1105]--[@b35-br-0-0-1105]). Identification of genetic variants that confer susceptibility to T2DM, MetS, and hyperuricemia are thus clinically important to prevent these conditions. We have now performed EWASs for T2DM, MetS, and hyperuricemia in early-onset subjects with these conditions who likely had greater genetic components compared with late-onset individuals.

In the T2DM study, rs150552771 of *LPGAT1*, rs140232911 of *ZNF860*, and rs141569282 of *OR4F6* were significantly associated with early-onset T2DM. None of these genes was shown to be associated with T2DM or diabetes-related traits in the previous GWASs. Given that rs150552771 of *LPGAT1* was not related to FPG level or blood hemoglobin A~1c~ content, *LPGAT1* was removed from new susceptibility locus, even though this discrepancy may be attributable to the effect of medical treatment for T2DM. We have thus newly identified *ZNF860* and *OR4F6* as susceptibility loci for T2DM. A SNP rs141569282 of *OR4F6* was significantly related to FPG level and blood hemoglobin A~1c~ content with the minor *A* allele being related to decreases in these parameters, while rs140232911 of *ZNF860* was related to blood hemoglobin A~1c~ content with the minor *T* allele being related to an increase in this parameter. Analyses of these traits as well as logistic regression analysis indicate that the *A* allele of rs141569282 in *OR4F6* is protective against T2DM, whereas the *T* allele of rs140232911 in *ZNF860* is a risk factor for this condition.

In the MetS study, six SNPs in five genes and one chromosomal locus were significantly associated with early-onset MetS. Of these genes and locus, *HLA-DQB2* ([@b63-br-0-0-1105]), rs17482753 at 8p21.3 ([@b63-br-0-0-1105]), and *APOA5* ([@b63-br-0-0-1105]) were previously shown to be related to lipid profiles; and *CCDC6* to serum uric acid level ([@b46-br-0-0-1105]). *OR52E4* or *OR4F6* has not been shown to be associated with MetS or MetS-related traits in the previous GWASs. A SNP rs11823828 of *OR52E4* was significantly related to serum concentrations of triglycerides and HDL-cholesterol, systolic BP, and FPG level; and rs141569282 of *OR4F6* to all traits. We have thus newly identified *OR52E4* and *OR4F6* as susceptibility loci for MetS. The minor *G* allele of rs11823828 in *OR52E4* was significantly related to increased serum triglycerides, decreased serum HDL-cholesterol, increased systolic BP, and increased FPG level, whereas the minor *A* allele of rs141569282 in *OR4F6* was related to reduced waist circumference, decreased serum triglycerides, increased serum HDL-cholesterol, decreased systolic and diastolic BP, and reduced FPG level. Analyses of these traits and logistic regression analysis indicate that the *G* allele of rs11823828 in *OR52E4* represents a risk factor for MetS, whereas the *A* allele of rs141569282 in *OR4F6* is protective against this condition.

In the hyperuricemia study, 9 SNPs in seven genes and one chromosomal locus were significantly associated with early-onset hyperuricemia. Of these genes and locus, *SLC2A9* ([@b46-br-0-0-1105]), *SLC22A12* ([@b46-br-0-0-1105]), and *BRAP* ([@b46-br-0-0-1105]) were previously shown to be related to serum uric acid level; and rs12229654 at 12q24.1 ([@b64-br-0-0-1105]), *ACAD10* ([@b63-br-0-0-1105]), and *HECTD4* ([@b63-br-0-0-1105]) to lipid profiles. *HERPUD2* or *CCDC63* has not been shown to be associated with hyperuricemia, gout, or serum uric acid level in the previous GWASs. A SNP rs2305335 of *HERPUD2* was significantly related to the serum uric acid level, whereas two SNPs of *CCDC63* were not related to this parameter. Therefore *CCDC63* was removed from new loci. We have thus newly identified *HERPUD2* as a susceptibility locus for hyperuricemia. The minor *A* allele of rs2305335 in *HERPUD2* was significantly related to increased serum uric acid. Examination of this trait and logistic regression analysis indicate that the *A* allele of rs2305335 in *HERPUD2* represents a risk factor or hyperuricemia. Furthermore, *OR4F6* was significantly associated with both T2DM and MetS. We thus newly identified four genes (*ZNF860, OR4F6, OR52E4, HERPUD2*) that confer susceptibility to early-onset T2DM, MetS, or hyperuricemia.

We previously showed that four, five, or three SNPs were related to T2DM (P\<1.44×10^−4^), MetS (P\<0.05), or hyperuricemia (P\<0.05) determined by multivariable logistic regression analysis with adjustment for age and sex after the initial EWAS screening of allele frequencies in both early-onset and late-onset individuals with these conditions ([@b54-br-0-0-1105]--[@b56-br-0-0-1105]). The relationship of two of four SNPs \[rs138313632 (P=1.11×10^−7^), rs139012426 (P=4.29×10^−5^)\] to T2DM were replicated (P\<0.05) in the present study. The relationship of two of five SNPs \[rs1007732 (P=0.0405), rs7350481 (P=3.17×10^−5^)\] to MetS were replicated in the present study. The relationship of two of three SNPs \[rs115445569 (P=0.0205), rs60854092 (P=0.0490)\] to hyperuricemia were replicated in the present study. These results suggest that genetic variants associated with T2DM, MetS, or hyperuricemia differ, in part, between early-onset and late-onset individuals with these conditions.

There are several limitations to our study: i) Given that the results were not replicated, their validation will be necessary in independent study populations or in other ethnic groups. ii) It is possible that SNPs identified in the present study are in LD with other genetic variants in the same gene or in other nearby genes that are actually responsible for the development of T2DM, MetS, or hyperuricemia. iii) The functional relevance of identified SNPs to the pathogenesis of T2DM, MetS, or hyperuricemia remains to be elucidated.

In conclusion, we have newly identified four genes (*ZNF860, OR4F6, OR52E4, HERPUD2*) that confer susceptibility to early-onset T2DM, MetS, or hyperuricemia. Determination of genotypes for the SNPs in these genes may prove informative for assessment of the genetic risk for T2DM, MetS, or hyperuricemia in Japanese.
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###### 

Characteristics of subjects with type 2 diabetes mellitus and control individuals.

  Characteristic                    Control       Type 2 diabetes mellitus   P-value
  --------------------------------- ------------- -------------------------- ----------
  No. of subjects                   5,711         1,696                      
  Age (years)                         50.4±10.2   56.3±7.2                   \<0.0001
  Sex (men/women, %)                52.1/47.9     76.2/23.8                  \<0.0001
  Smoking (%)                       40.0          47.5                         0.0105
  Obesity (%)                       28.1          45.2                       \<0.0001
  Body mass index (kg/m^2^)         22.9±3.3      24.7±3.9                   \<0.0001
  Hypertension (%)                  32.0          71.0                       \<0.0001
  Systolic BP (mmHg)                122±20        140±27                     \<0.0001
  Diastolic BP (mmHg)                 75±13         80±15                    \<0.0001
  Fasting plasma glucose (mmol/l)     5.17±0.48     8.95±3.77                \<0.0001
  Blood hemoglobin A~1c~ (%)          5.48±0.31     7.33±1.87                \<0.0001
  Dyslipidemia (%)                  54.4          80.2                       \<0.0001
  Serum triglycerides (mmol/l)        1.29±0.89     1.82±1.47                \<0.0001
  Serum HDL-cholesterol (mmol/l)      1.62±0.46     1.32±0.43                \<0.0001
  Serum LDL-cholesterol (mmol/l)      3.14±0.82     3.15±0.97                  0.8052
  Chronic kidney disease (%)        10.9          26.8                       \<0.0001
  Serum creatinine (µmol/l)           70.4±63.1     93.1±122.6               \<0.0001
  eGFR (ml min^−1^ 1.73 m^−2^)        78.4±18.9     73.2±24.6                \<0.0001
  Hyperuricemia (%)                 14.5          22.9                       \<0.0001
  Serum uric acid (µmol/l)          321±90          340±102                  \<0.0001

Quantitative data are means ± standard deviations and were compared between subjects with type 2 diabetes mellitus and controls with the unpaired Student\'s t-test. Categorical data were compared between two groups with Pearson\'s Chi-square test. Based on Bonferroni\'s correction, a P-value of \<0.0026 (0.05/19) was considered statistically significant. Definitions of diseases: Obesity, body mass index of ≥25 kg/m^2^; hypertension, systolic BP of ≥140 mmHg, diastolic BP of ≥90 mmHg, or taking of anti-hypertensive medication; dyslipidemia, serum triglyceride concentration of ≥1.65 mmol/l, serum HDL-cholesterol concentration of \<1.04 mmol/l, serum LDL-cholesterol concentration of ≥3.64 mmol/l, or taking of anti-dyslipidemic medication; chronic kidney disease, eGFR of \<60 ml min^−1^ 1.73 m^−2^; hyperuricemia, serum uric acid concentration of \>416 µmol/l or taking of uric acid-lowering medication. BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate.

###### 

Characteristics of subjects with metabolic syndrome and control individuals.

  Characteristic                    Control       Metabolic syndrome   P-value
  --------------------------------- ------------- -------------------- ----------
  No. of subjects                   1,919         2,296                
  Age (years)                         47.0±10.7   55.0±8.0             \<0.0001
  Sex (men/women, %)                42.3/57.7     67.9/32.1            \<0.0001
  Smoking (%)                       35.2          46.1                 \<0.0001
  Waist circumference (cm)          74.0±6.0      88.3±9.0             \<0.0001
  Body mass index (kg/m^2^)         20.8±2.2      26.0±3.7             \<0.0001
  Systolic BP (mmHg)                109±11        140±25               \<0.0001
  Diastolic BP (mmHg)               67±9            83±14              \<0.0001
  Fasting plasma glucose (mmol/l)     4.97±0.36     7.25±3.07          \<0.0001
  Blood hemoglobin A~1c~ (%)          5.39±0.29     6.58±1.60          \<0.0001
  Serum triglycerides (mmol/l)        0.82±0.30     2.17±1.46          \<0.0001
  Serum HDL-cholesterol (mmol/l)      1.86±0.42     1.24±0.37          \<0.0001
  Serum LDL-cholesterol (mmol/l)      2.95±0.74     3.28±0.96          \<0.0001
  Chronic kidney disease (%)        15.9          56.6                 \<0.0001
  Serum creatinine (µmol/l)           63.0±18.2     84.4±97.5          \<0.0001
  eGFR (ml min^−1^ 1.73 m^−2^)        81.6±17.0     73.3±23.5          \<0.0001
  Hyperuricemia (%)                 5.2           28.0                 \<0.0001
  Serum uric acid (µmol/l)          286±76        356±97               \<0.0001

Quantitative data are means ± standard deviations and were compared between subjects with metabolic syndrome and controls with the unpaired Student\'s t-test. Categorical data were compared between two groups with Pearson\'s Chi-square test. Base on Bonferroni\'s correction, a P-value of \<0.0029 (0.05/17) was considered statistically significant. BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate. Definitions of chronic kidney disease and hyperuricemia are described in [Table I](#tI-br-0-0-1105){ref-type="table"}.

###### 

Characteristics of subjects with hyperuricemia and control individuals.

  Characteristic                    Control       Hyperuricemia   P-value
  --------------------------------- ------------- --------------- ----------
  No. of subjects                   6,554         1,365           
  Age (years)                       51.5±9.9      52.9±9.1        \<0.0001
  Sex (men/women, %)                52.6/47.4     90.2/9.8        \<0.0001
  Smoking (%)                       38.3          61.6            \<0.0001
  Obesity (%)                       30.0          47.4            \<0.0001
  Body mass index (kg/m^2^)         23.2±3.5      24.8±3.8        \<0.0001
  Hypertension (%)                  38.2          62.0            \<0.0001
  Systolic BP (mmHg)                126±23        134±24          \<0.0001
  Diastolic BP (mmHg)                 75±14         82±15         \<0.0001
  Diabetes mellitus (%)             20.8          31.6            \<0.0001
  Fasting plasma glucose (mmol/l)     6.04±2.38     6.25±2.27       0.0022
  Blood hemoglobin A~1c~ (%)          5.96±1.26     6.10±1.28       0.0042
  Dyslipidemia (%)                  57.9          79.0            \<0.0001
  Serum triglycerides (mmol/l)        1.34±0.99     1.90±1.38     \<0.0001
  Serum HDL-cholesterol (mmol/l)      1.57±0.47     1.37±0.42     \<0.0001
  Serum LDL-cholesterol (mmol/l)      3.15±0.85     3.20±0.93       0.0506
  Chronic kidney disease (%)        11.0          33.0            \<0.0001
  Serum creatinine (µmol/l)           68.7±52.3     109.4±150.3   \<0.0001
  eGFR (ml min^−1^ 1.73 m^−2^)        79.2±18.3     67.4±25.8     \<0.0001
  Serum uric acid (µmol/l)          296±67        455±78          \<0.0001

Quantitative data are means ± standard deviations and were compared between subjects with hyperuricemia and controls with the unpaired Student\'s t-test. Categorical data were compared between two groups with Pearson\'s Chi-square test. Base on Bonferroni\'s correction, a P-value of \<0.0026 (0.05/19) was considered statistically significant. Definition of diabetes mellitus, fasting plasma glucose level of ≥6.93 mmol/l, blood hemoglobin A~1c~ content of ≥6.5%, or taking of antidiabetes medication. Definitions of other diseases are described in [Table I](#tI-br-0-0-1105){ref-type="table"}. BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate.

###### 

The four SNPs significantly (P\<1.60×10^−6^) associated with type 2 diabetes mellitus in the exome-wide association study.

  Gene       SNP           Nucleotide substitution^[a](#tfn5-br-0-0-1105){ref-type="table-fn"}^   Amino acid substitution   Chromosome   Position    MAF (%)   Allele odds ratio   P-value (allele frequency)
  ---------- ------------- ---------------------------------------------------------------------- ------------------------- ------------ ----------- --------- ------------------- ----------------------------
  *OR4F6*    rs141569282   G/A                                                                    A117T                     15           101806068     1.7       0.29              2.45×10^−12^
  *ZNF860*   rs140232911   C/T                                                                    S161L                       3          31989561    10.4        3.67              1.25×10^−8^
  *LPGAT1*   rs150552771   T/C                                                                    K200E                       1          211783358     5.0     20.00               2.08×10^−8^
  *KRR1*     rs17115182    G/A                                                                    P43S                      12           75508405      7.0       3.57              8.08×10^−7^

Allele frequencies were analyzed with Fisher\'s exact test.

Major allele/minor allele. MAF, minor allele frequency; SNP, single nucleotide polymorphism.

###### 

The six SNPs significantly (P\<1.59×10^−6^) associated with metabolic syndrome in the exome-wide association study.

  Gene         SNP           Nucleotide substitution^[a](#tfn7-br-0-0-1105){ref-type="table-fn"}^   Amino acid substitution   Chromosome   Position    MAF (%)   Allele odds ratio   P-value (allele frequency)
  ------------ ------------- ---------------------------------------------------------------------- ------------------------- ------------ ----------- --------- ------------------- ----------------------------
  *CCDC6*      rs1053266     A/C                                                                    T470P                     10           59792934    28.6      2.33                3.18×10^−52^
  *APOA5*      rs2075291     G/T                                                                    G185C                     11           116790676     7.3     1.72                3.94×10^−11^
  *OR4F6*      rs141569282   G/A                                                                    A117T                     15           101806068     1.7     0.34                1.35×10^−10^
  *HLA-DQB2*   rs200716952   C/T                                                                    A167T                       6          32758997      2.5     0.47                2.15×10^−10^
  *OR52E4*     rs11823828    T/G                                                                    F227L                     11           5884973     36.6      1.27                7.99×10^−7^
               rs17482753    G/T                                                                                                8          19975135    12.6      0.73                1.55×10^−6^

Allele frequencies were analyzed with Fisher\'s exact test.

Major allele/minor allele. MAF, minor allele frequency; SNP, single nucleotide polymorphism.

###### 

The nine SNPs significantly (P\<1.61×10^−6^) associated with hyperuricemia in the exome-wide association study.

  Gene         SNP           Nucleotide substitution^[a](#tfn9-br-0-0-1105){ref-type="table-fn"}^   Amino acid substitution   Chromosome   Position    MAF (%)   Allele odds ratio   P-value (allele frequency)
  ------------ ------------- ---------------------------------------------------------------------- ------------------------- ------------ ----------- --------- ------------------- ----------------------------
  *SLC22A12*   rs121907892   G/A                                                                    W224\*                    11           64593747      2.4     0.07                3.13×10^−24^
  *BRAP*       rs3782886     A/G                                                                                              12           111672685   29.3      0.73                1.78×10^−11^
  *ACAD10*     rs11066015    G/A                                                                                              12           111730205   27.5      0.73                7.72×10^−11^
  *HECTD4*     rs11066280    T/A                                                                                              12           112379979   29.0      0.75                1.36×10^−9^
               rs12229654    T/G                                                                                              12           110976657   22.5      0.74                1.83×10^−9^
  *SLC2A9*     rs3775948     G/C                                                                                                4          9993558     42.4      0.80                1.49×10^−7^
  *HERPUD2*    rs2305335     T/A                                                                    L200H                       7          35638368      1.6     2.13                2.63×10^−7^
  *CCDC63*     rs10774610    T/C                                                                                              12           110902439   23.7      0.78                1.14×10^−6^
  *CCDC63*     rs10849915    T/C                                                                                              12           110895818   23.6      0.78                1.23×10^−6^

Allele frequencies were analyzed with Fisher\'s exact test.

Major allele/minor allele. MAF, minor allele frequency; SNP, single nucleotide polymorphism. \*, stop codon.

###### 

Association of SNPs to type 2 diabetes mellitus as determined by multivariable logistic regression analysis.

                                 Dominant   Recessive   Additive 1      Additive 2                                                   
  ---------- ------------- ----- ---------- ----------- --------------- ------------ -- -- ---------- -------- --------------- -- -- --
  *OR4F6*    rs141569282   G/A   \<0.0001     0.31      0.21--0.47                         \<0.0001     0.31   0.21--0.47            
  *ZNF860*   rs140232911   C/T     0.0005     2.26      1.43--3.59                           0.0005     2.26   1.43--3.59            
  *LPGAT1*   rs150552771   T/C     0.0001   12.09         3.40--43.00                        0.0001   12.09      3.40--43.00         

Multivariable logistic regression analysis was performed with adjustment for age and sex. Based on Bonferroni\'s correction; P-value of \<0.0031 (0.05/16) was considered statistically significant. OR, odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism.

###### 

Relation of SNPs to metabolic syndrome as determined by multivariable logistic regression analysis.

                                   Dominant   Recessive   Additive 1   Additive 2                                                                        
  ------------ ------------- ----- ---------- ----------- ------------ ------------ ------ ------------ ---------- ------ ------------ ---------- ------ ------------
  *CCDC6*      rs1053266     A/C   \<0.0001   1.97        1.70--2.28   \<0.0001     2.73   1.96--3.78   \<0.0001   1.79   1.53--2.09   \<0.0001   3.28   2.36--4.57
  *APOA5*      rs2075291     G/T   \<0.0001   1.85        1.51--2.25     0.1335                         \<0.0001   1.84   1.50--2.25     0.0947          
  *OR4F6*      rs141569282   G/A   \<0.0001   0.37        0.25--0.54                                    \<0.0001   0.37   0.25--0.54                     
  *HLA-DQB2*   rs200716952   C/T   \<0.0001   0.58        0.44--0.76                                    \<0.0001   0.58   0.44--0.76                     
  *OR52E4*     rs11823828    T/G   0.0177     1.19        1.03--1.37   \<0.0001     1.76   1.43--2.17     0.6181                       \<0.0001   1.80   1.44--2.24
               rs17482753    G/T   0.0003     0.74        0.63--0.87     0.5086                           0.0003   0.74   0.63--0.87     0.3690          

Multivariable logistic regression analysis was performed with adjustment for age and sex. Based on Bonferroni\'s correction; P-value of \<0.0021 (0.05/24) was considered statistically significant. OR, odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism.

###### 

Association of SNPs to hyperuricemia as determined by multivariable logistic regression analysis.

                                   Dominant   Recessive   Additive 1   Additive 2                                                                        
  ------------ ------------- ----- ---------- ----------- ------------ ------------ ------ ------------ ---------- ------ ------------ ---------- ------ ------------
  *SLC22A12*   rs121907892   G/A   \<0.0001   0.06        0.03--0.14     0.9959                         \<0.0001   0.06   0.03--0.14     0.9959          
  *BRAP*       rs3782886     A/G   \<0.0001   0.66        0.58--0.74   \<0.0001     0.53   0.42--0.67   \<0.0001   0.71   0.62--0.81   \<0.0001   0.45   0.36--0.58
  *ACAD10*     rs11066015    G/A   \<0.0001   0.66        0.58--0.75   \<0.0001     0.51   0.40--0.66   \<0.0001   0.72   0.63--0.82   \<0.0001   0.45   0.35--0.57
  *HECTD4*     rs11066280    T/A   \<0.0001   0.69        0.61--0.78   \<0.0001     0.53   0.42--0.67   \<0.0001   0.75   0.66--0.86   \<0.0001   0.47   0.37--0.60
               rs12229654    T/G   \<0.0001   0.69        0.61--0.78   \<0.0001     0.47   0.34--0.64   \<0.0001   0.74   0.65--0.84   \<0.0001   0.42   0.31--0.58
  *SLC2A9*     rs3775948     G/C   \<0.0001   0.77        0.68--0.88   \<0.0001     0.67   0.57--0.80     0.0109   0.84   0.73--0.96   \<0.0001   0.61   0.50--0.73
  *HERPUD2*    rs2305335     T/A   \<0.0001   1.89        1.40--2.53     0.4553                         \<0.0001   1.88   1.40--2.52     0.4345          
  *CCDC63*     rs10774610    T/C   \<0.0001   0.71        0.62--0.80     0.0048     0.67   0.51--0.89   \<0.0001   0.73   0.64--0.83     0.0003   0.60   0.45--0.79
  *CCDC63*     rs10849915    T/C   \<0.0001   0.71        0.62--0.80     0.0036     0.66   0.50--0.87   \<0.0001   0.73   0.64--0.83     0.0002   0.59   0.44--0.78

Multivariable logistic regression analysis was performed with adjustment for age and sex. Based on Bonferroni\'s correction; P-value of \<0.0014 (0.05/36) was considered statistically significant. OR, odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism.

###### 

Relation of SNPs identified in the present study to fasting plasma glucose level and blood hemoglobin A~1c~ content.

  Gene       SNP           Pasting plasma glucose (mmol/l)   P-value     Blood hemoglobin A~1c~ (%)   P-value                                
  ---------- ------------- --------------------------------- ----------- ---------------------------- -------------- ----------- ----------- --------------
  *OR4F6*    rs141569282   G/A                               GG          GA                           **\<0.0001**   GG          GA          **\<0.0001**
                                                             6.26±2.76   5.35±0.71                                   6.15±1.46   5.57±0.43   
  *ZNF860*   rs140232911   C/T                               CC          CT                             0.6279       CC          CT            **0.0070**
                                                             6.06±2.46   6.25±1.97                                   5.52±0.73   6.00±1.32   
  *LPGAT1*   rs150552771   T/C                               TT          TC                             0.6320       TT          TC            0.3280
                                                             6.05±2.45   6.63±3.88                                   5.35±0.53   5.99±1.31   

Data are means ± standard deviations and compared among genotypes by one-way analysis of variance. Based on Bonferroni\'s correction, P-values of \<0.0083 (0.05/6) were considered statistically significant and are shown in bold. SNP, single nucleotide polymorphism.

###### 

Relationship of SNPs identified in the present study to each trait of metabolic syndrome.

  Gene         SNP           Waist circumference (cm)              P-value                               
  ------------ ------------- ------------------------------------- ------------- ----------- ----------- --------------
  *CCDC6*      rs1053266     A/C                                   AA            AC          CC          **\<0.0001**
                                                                   81.0±10.6     83.8±10.4   87.0±8.6    
  *APOA5*      rs2075291     G/T                                   GG            GT          TT          **0.0012**
                                                                   82.0±10.6     83.7±10.3   82.8±10.3   
  *OR4F6*      rs141569282   G/A                                   GG            GA                      **\<0.0001**
                                                                   83.2±10.4     79.1±10.8               
  *HLA-DQB2*   rs200716952   C/T                                   CC            CT                      **\<0.0001**
                                                                   82.5±10.5     79.5±10.7               
  *OR52E4*     rs11823828    T/G                                   TT            TG          GG            0.0159
                                                                   81.8±10.8     81.8±10.8   83.2±10.3   
               rs17482753    G/T                                   GG            GT          TT            0.0070
                                                                   82.5±10.7     81.3±10.3   83.2±10.9   
                                                                                                         
  **Gene**     **SNP**       **Serum triglycerides (mmol/l)**      **P-value**                           
                                                                                                         
  *CCDC6*      rs1053266     A/C                                   AA            AC          CC          **\<0.0001**
                                                                   1.45±1.21     1.79±1.46   2.13±1.33   
  *APOA5*      rs2075291     G/T                                   GG            GT          TT          **\<0.0001**
                                                                   1.51±1.15     2.06±1.84   2.71±2.63   
  *OR4F6*      rs141569282   G/A                                   GG            GA                      **\<0.0001**
                                                                   1.71±1.38     1.19±1.00               
  *HLA-DQB2*   rs200716952   C/T                                   CC            CT                      **\<0.0001**
                                                                   1.62±1.32     1.26±1.11               
  *OR52E4*     rs11823828    T/G                                   TT            TG          GG            **0.0003**
                                                                   1.52±1.22     1.49±1.15   1.74±1.41   
               rs17482753    G/T                                   GG            GT          TT          **\<0.0001**
                                                                   1.65±1.32     1.41±1.22   1.55±1.72   
                                                                                                         
  **Gene**     **SNP**       **Serum HDL-cholesterol (mmol/l)**    **P-value**                           
                                                                                                         
  *CCDC6*      rs1053266     A/C                                   AA            AC          CC          **\<0.0001**
                                                                   1.59±0.49     1.39±0.48   1.17±0.35   
  *APOA5*      rs2075291     G/T                                   GG            GT          TT          **\<0.0001**
                                                                   1.53±0.50     1.38±0.48   1.28±0.43   
  *OR4F6*      rs141569282   G/A                                   GG            GA                      **\<0.0001**
                                                                   1.44±0.49     1.72±0.42               
  *HLA-DQB2*   rs200716952   C/T                                   CC            CT                      **\<0.0001**
                                                                   1.49±0.47     1.69±0.47               
  *OR52E4*     rs11823828    T/G                                   TT            TG          GG            **0.0001**
                                                                   1.54±0.49     1.54±0.51   1.44±0.47   
               rs17482753    G/T                                   GG            GT          TT          **\<0.0001**
                                                                   1.48±0.49     1.58±0.53   1.62±0.52   
                                                                                                         
  **Gene**     **SNP**       **Systolic blood pressure (mmHg)**    **P-value**                           
                                                                                                         
  *CCDC6*      rs1053266     A/C                                   AA            AC          CC          **\<0.0001**
                                                                   122±22        134±28      145±26      
  *APOA5*      rs2075291     G/T                                   GG            GT          TT            0.0493
                                                                   127±25        130±24      132±30      
  *OR4F6*      rs141569282   G/A                                   GG            GA                      **\<0.0001**
                                                                   131±27        115±16                  
  *HLA-DQB2*   rs200716952   C/T                                   CC            CT                      **\<0.0001**
                                                                   128±26        117±17                  
  *OR52E4*     rs11823828    T/G                                   TT            TG          GG          **\<0.0001**
                                                                   125±24        126±25      130±25      
               rs17482753    G/T                                   GG            GT          TT            0.0616
                                                                   128±25        126±25      130±23      
                                                                                                         
  **Gene**     **SNP**       **Diastolic blood pressure (mmHg)**   **P-value**                           
                                                                                                         
  *CCDC6*      rs1053266     A/C                                   AA            AC          CC          **\<0.0001**
                                                                   75±14         79±16       82±16       
  *APOA5*      rs2075291     G/T                                   GG            GT          TT            0.0055
                                                                   76±15         78±14       80±13       
  *OR4F6*      rs141569282   G/A                                   GG            GA                      **\<0.0001**
                                                                   78±15         71±13                   
  *HLA-DQB2*   rs200716952   C/T                                   CC            CT                        **0.0002**
                                                                   77±15         73±13                   
  *OR52E4*     rs11823828    T/G                                   TT            TG          GG            0.5502
                                                                   76±15         76±15       76±14       
               rs17482753    G/T                                   GG            GT          TT            0.3685
                                                                   76±15         76±15       77±14       
                                                                                                         
  **Gene**     **SNP**       **Fasting plasma glucose (mmol/l)**   **P-value**                           
                                                                                                         
  *CCDC6*      rs1053266     A/C                                   AA            AC          CC          **\<0.0001**
                                                                   5.90±2.05     6.90±3.33   7.41±3.02   
  *APOA5*      rs2075291     G/T                                   GG            GT          TT            0.2227
                                                                   6.25±2.57     6.46±2.77   6.15±1.77   
  *OR4F6*      rs141569282   G/A                                   GG            GA                      **\<0.0001**
                                                                   6.53±2.87     5.34±0.76               
  *HLA-DQB2*   rs200716952   C/T                                   CC            CT                      **\<0.0001**
                                                                   6.36±2.67     5.41±1.05               
  *OR52E4*     rs11823828    T/G                                   TT            TG          GG            **0.0001**
                                                                   6.09±2.32     6.07±2.30   6.57±2.95   
               rs17482753    G/T                                   GG            GT          TT            0.0048
                                                                   6.35±2.63     6.03±2.42   6.55±2.78   

Data are means ± standard deviations and compared among genotypes by one-way analysis of variance. Based on Bonferroni\'s correction, P-values of \<0.0014 (0.05/36) were considered statistically significant and are shown in bold. SNP, single nucleotide polymorphism.

###### 

Relationship of SNPs identified in the present study to the serum concentration of uric acid.

  Gene         SNP           Serum uric acid (µmol/l)   P-value                      
  ------------ ------------- -------------------------- --------- --------- -------- --------------
  *SLC22A12*   rs121907892   G/A                        GG        GA        AA       **\<0.0001**
                                                        333±91    231±82    52±19    
  *BRAP*       rs3782886     A/G                        AA        AG        GG         **0.0002**
                                                        332±97    324±91    318±88   
  *ACAD10*     rs11066015    G/A                        GG        GA        AA         **0.0004**
                                                        332±97    324±91    319±88   
  *HECTD4*     rs11066280    T/A                        TT        TA        AA         **0.0006**
                                                        332±96    325±92    318±87   
               rs12229654    T/G                        TT        TG        GG         **0.0002**
                                                        331±96    326±91    312±84   
  *SLC2A9*     rs3775948     G/C                        GG        GC        CC       **\<0.0001**
                                                        335±94    328±92    312±96   
  *HERPUD2*    rs2305335     T/A                        TT        TA        AA       **\<0.0001**
                                                        327±93    358±116   407±88   
  *CCDC63*     rs10774610    T/C                        TT        TC        CC         0.0067
                                                        330±96    325±91    318±92   
  *CCDC63*     rs10849915    T/C                        TT        TC        CC         0.0083
                                                        330±96    325±91    318±92   

Data were means ± standard deviations and compared among genotypes by one-way analysis of variance. Based on Bonferroni\'s correction, P-values of \<0.0056 (0.05/9) were considered statistically significant and are shown in bold. SNP, single nucleotide polymorphism.

###### 

Relationship of genes and SNPs associated with type 2 diabetes mellitus in the present study to previously reported diabetes-related phenotypes.

  Gene       SNP           Chromosome   Position    Previously reported phenotypes
  ---------- ------------- ------------ ----------- --------------------------------
  *LPGAT1*   rs150552771     1          211783358   None
  *ZNF860*   rs140232911     3          31989561    None
  *OR4F6*    rs141569282   15           101806068   None

Data were obtained from Genome-wide repository of associations between SNPs and phenotypes (GRASP) search database (<https://grasp.nhlbi.nih.gov/Search.aspx>) with a P-value of \<1.0×10^−6^. SNP, single nucleotide polymorphism.

###### 

Relationship of genes, chromosomal locus, and SNPs associated with metabolic syndrome in the present study to previously reported metabolic disease-related phenotypes.

  Gene/chr. locus   SNP           Chr.   Position    Previously reported phenotypes
  ----------------- ------------- ------ ----------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *HLA-DQB2*        rs200716952     6    32758997    Type 1 diabetes (17554300, 17632545), total cholesterol (20686565)
  8p21.3            rs17482753      8    19975135    Triglycerides (20686565, 23063622, 19060906, 18193043, 21943158, 18179892, 19913121, 17463246), HDL-cholesterol (20686565, 23063622, 19060906, 21943158, 20031538, 20370913, 20339536, 19913121)
  *CCDC6*           rs1053266     10     59792934    Serum urate (23263486)
  *OR52E4*          rs11823828    11     5884973     None
  *APOA5*           rs2075291     11     116790676   Triglycerides (20686565, 23063622, 22629316, 19060906, 21943158, 19913121, 18193043, 19802338, 23505323, 23236364, 21386085, 19197348), HDL-cholesterol (23063622, 22629316, 20686565, 21386085, 19913121, 23236364), LDL-cholesterol (20686565, 19913121), total cholesterol (20686565, 23063622, 20339536, 18179892)
  *OR4F6*           rs141569282   15     101806068   None

Data were obtained from Genome-wide repository of associations between SNPs and phenotypes (GRASP) search database (<https://grasp.nhlbi.nih.gov/Search.aspx>) with a P-value of \<1.0×10^−6^. Numbers in parentheses are PubMed IDs. SNP, single nucleotide polymorphism; Chr., chromosome.

###### 

Relationship of genes, chromosomal locus, and SNPs associated with hyperuricemia in the present study to previously reported metabolic disease-related phenotypes.

  Gene/chr. locus   SNP           Chr.   Position    Previously reported phenotypes
  ----------------- ------------- ------ ----------- ------------------------------------------------------------------------------------------------------------------------
  *SLC2A9*          rs3775948       4    9993558     Serum urate (23263486)
  *HERPUD2*         rs2305335       7    35638368    None
  *SLC22A12*        rs121907892   11     64593747    Serum urate (20139978, 23263486, 21768215, 20884846, 19503597)
  *CCDC63*          rs10849915    12     110895818   None
                    rs10774610    12     110902439   None
  12q24.1           rs12229654    12     110976657   HDL-cholesterol (21909109)
  *BRAP*            rs3782886     12     111672685   Serum urate (23263486)
  *ACAD10*          rs11066015    12     111730205   LDL-cholesterol (20686565), type 1 diabetes (17554300)
  *HECTD4*          rs11066280    12     112379979   HDL-cholesterol (21572416, 21909109, 22751097), LDL-cholesterol (21572416, 20686565), fasting blood glucose (23575436)

Data were obtained from Genome-wide repository of associations between SNPs and phenotypes (GRASP) search database (<https://grasp.nhlbi.nih.gov/Search.aspx>) with a P-value of \<1.0×10^−6^. Numbers in parentheses are PubMed IDs. SNP, single nucleotide polymorphism; Chr., chromosome.
